Amarant Groep

amarantgroep.nl

The ‘Amarant Groep’ is a large healthcare organisation in the province Noord-Brabant, the Netherlands, providing care to clients in every stage of life. The client perspective is always central. All efforts and innovations are focused on the clients doing it themselves, get involved and their quality of life. The Amarant Groep is the total of the following three brand names.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

news image

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

news image

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More

Cell and Gene Therapy, Industrial Impact

BIOCYTOGEN LAUNCHES RENNANO™ MOUSE, A FULLY HUMAN HEAVY CHAIN ANTIBODY PLATFORM

Biocytogen | January 05, 2023

news image

RenNano™, a fully human heavy-chain antibody platform developed by Biocytogen Pharmaceuticals Co., Ltd., has been launched officially. RenNano™ joins RenMab™ and RenLite® as the newest member of the RenMice™ family. All three RenMice™ technologies from Biocytogen work together to speed up the search and development of entirely human monoclonal, bispecific/multispecific, and single-domain antibodies (sdAbs, or nanobodies). Camels and sharks produce...

Read More

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

news image

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More
news image

MedTech

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More
news image

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIOCYTOGEN LAUNCHES RENNANO™ MOUSE, A FULLY HUMAN HEAVY CHAIN ANTIBODY PLATFORM

Biocytogen | January 05, 2023

RenNano™, a fully human heavy-chain antibody platform developed by Biocytogen Pharmaceuticals Co., Ltd., has been launched officially. RenNano™ joins RenMab™ and RenLite® as the newest member of the RenMice™ family. All three RenMice™ technologies from Biocytogen work together to speed up the search and development of entirely human monoclonal, bispecific/multispecific, and single-domain antibodies (sdAbs, or nanobodies). Camels and sharks produce...

Read More
news image

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More